Comparative Pharmacology
Head-to-head clinical analysis: NOVAMINE 15 SULFITE FREE IN PLASTIC CONTAINER versus NOVAMINE 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVAMINE 15 SULFITE FREE IN PLASTIC CONTAINER versus NOVAMINE 8 5.
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER vs NOVAMINE 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acid mixture for parenteral nutrition; provides essential and nonessential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate oral or enteral nutrition.
Novamine 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in patients who cannot obtain adequate nutrition enterally.
Administered intravenously. Initial dose: 0.6-1.0 g amino acids/kg/day (4-6.7 mL/kg/day) infused over 12-24 hours. Maximum: 2 g amino acids/kg/day (13.3 mL/kg/day).
500 mL to 2000 mL intravenously per 24 hours, typically infused at a rate of 20 to 40 mL/hour; adjust based on metabolic and clinical response.
None Documented
None Documented
Variable; depends on individual metabolic and nutritional status; typical terminal half-life of infused amino acids is approximately 1-2 hours after infusion cessation, reflecting rapid clearance from plasma.
Variable; amino acids have short t1/2 of minutes to hours. Clinical context: continuous infusion maintains steady state; elimination depends on metabolic demand and organ function.
Amino acids are primarily excreted via renal mechanisms, with <5% excreted unchanged in urine; majority of nitrogen is reincorporated into protein synthesis or converted to urea and excreted renally.
Renal: >95% as amino acids and metabolites. Biliary/fecal: <5%.
Category C
Category C
Parenteral Nutrition
Parenteral Nutrition